These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37519418)

  • 21. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
    Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan.
    Isobe H; Mori K; Minato K; Katsura H; Taniguchi K; Arunachalam A; Kothari S; Cao X; Kato T
    Lung Cancer (Auckl); 2017; 8():191-206. PubMed ID: 29123433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
    Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
    Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
    Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
    Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
    Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
    Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.
    Gao G; Jia K; Zhao S; Li X; Zhao C; Jiang T; Su C; Ren S; Zhou F; Zhou C
    Transl Lung Cancer Res; 2019 Dec; 8(6):920-928. PubMed ID: 32010570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
    Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
    Quoix E; Zalcman G; Oster JP; Westeel V; Pichon E; Lavolé A; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Dansin E; Poudenx M; Molinier O; Vaylet F; Moro-Sibilot D; Herman D; Bennouna J; Tredaniel J; Ducoloné A; Lebitasy MP; Baudrin L; Laporte S; Milleron B;
    Lancet; 2011 Sep; 378(9796):1079-88. PubMed ID: 21831418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study.
    Nasu I; Kondo M; Uozumi R; Takada S; Nawata S; Iihara H; Okumura Y; Takemoto M; Mino K; Sasaki T; Hirose C; Aomori T; Shimano R; Maeno K; Oizumi S; Kusumoto S; Ohno Y; Ikemura S; Takai D; Hara A; Kawazoe H; Nakamura T
    J Cancer; 2023; 14(5):676-688. PubMed ID: 37056385
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment Patterns for Advanced Non-Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice.
    McKay C; Burke T; Cao X; Abernethy AP; Carbone DP
    Clin Lung Cancer; 2016 Sep; 17(5):449-460.e7. PubMed ID: 27157534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy.
    Valdes M; Nicholas G; Goss GD; Wheatley-Price P
    Curr Oncol; 2016 Dec; 23(6):386-390. PubMed ID: 28050134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
    Suzuki S; Haratani K; Hayashi H; Chiba Y; Tanizaki J; Kato R; Mitani S; Kawanaka Y; Kurosaki T; Hasegawa Y; Okabe T; Tanaka K; Akashi Y; Ozaki T; Nishio K; Ito A; Nakagawa K
    Eur J Cancer; 2022 Jan; 161():44-54. PubMed ID: 34922263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
    Saalfeld FC; Wenzel C; Christopoulos P; Merkelbach-Bruse S; Reissig TM; Laßmann S; Thiel S; Stratmann JA; Marienfeld R; Berger J; Desuki A; Velthaus JL; Kauffmann-Guerrero D; Stenzinger A; Michels S; Herold T; Kramer M; Herold S; Tufman A; Loges S; Alt J; Joosten M; Schmidtke-Schrezenmeier G; Sebastian M; Stephan-Falkenau S; Waller CF; Wiesweg M; Wolf J; Thomas M; Aust DE; Wermke M;
    J Thorac Oncol; 2021 Nov; 16(11):1952-1958. PubMed ID: 34245914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice.
    Liang YH; Shao YY; Liao BC; Lee HS; Yang JC; Chen HM; Chiang CJ; Cheng AL; Lai MS
    J Cancer; 2016; 7(11):1515-23. PubMed ID: 27471567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of immune checkpoint inhibitor therapy in patients with
    Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
    Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance.
    Ando C; Ichihara E; Yokoyama T; Inoue K; Tamura T; Fujiwara K; Oda N; Kano H; Kishino D; Watanabe K; Inoue M; Ochi N; Onishi F; Ichikawa H; Kobe H; Tachibana S; Hotta K; Maeda Y; Kiura K
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4933-4938. PubMed ID: 36308525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.